Cargando…
Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
PURPOSE: Magnetoliposomes (MLs) have shown great potential as magnetic resonance imaging contrast agents and as delivery vehicles for cancer therapy. Targeting the MLs towards the tumor cells or neovascularization could ensure delivery of drugs at the tumor site. In this study, we evaluated the pote...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681073/ https://www.ncbi.nlm.nih.gov/pubmed/31534330 http://dx.doi.org/10.2147/IJN.S214041 |
_version_ | 1783441648163749888 |
---|---|
author | Garcia Ribeiro, Rita Sofia Belderbos, Sarah Danhier, Pierre Gallo, Juan Manshian, Bella B Gallez, Bernard Bañobre, Manuel de Cuyper, Marcel Soenen, Stefaan J Gsell, Willy Himmelreich, Uwe |
author_facet | Garcia Ribeiro, Rita Sofia Belderbos, Sarah Danhier, Pierre Gallo, Juan Manshian, Bella B Gallez, Bernard Bañobre, Manuel de Cuyper, Marcel Soenen, Stefaan J Gsell, Willy Himmelreich, Uwe |
author_sort | Garcia Ribeiro, Rita Sofia |
collection | PubMed |
description | PURPOSE: Magnetoliposomes (MLs) have shown great potential as magnetic resonance imaging contrast agents and as delivery vehicles for cancer therapy. Targeting the MLs towards the tumor cells or neovascularization could ensure delivery of drugs at the tumor site. In this study, we evaluated the potential of MLs targeting the αvβ3 integrin overexpressed on tumor neovascularization and different tumor cell types, including glioma and ovarian cancer. METHODS: MLs functionalized with a Texas Red fluorophore (anionic MLs), and with the fluorophore and the cyclic Arginine-Glycine-Aspartate (cRGD; cRGD-MLs) targeting the αvβ3 integrin, were produced in-house. Swiss nude mice were subcutaneously injected with 10(7) human ovarian cancer SKOV-3 cells. Tumors were allowed to grow for 3 weeks before injection of anionic or cRGD-MLs. Biodistribution of MLs was followed up with a 7T preclinical magnetic resonance imaging (MRI) scanner and fluorescence imaging (FLI) right after injection, 2h, 4h, 24h and 48h post injection. Ex vivo intratumoral ML uptake was confirmed using FLI, electron paramagnetic resonance spectroscopy (EPR) and histology at different time points post injection. RESULTS: In vivo, we visualized a higher uptake of cRGD-MLs in SKOV-3 xenografts compared to control, anionic MLs with both MRI and FLI. Highest ML uptake was seen after 4h using MRI, but only after 24h using FLI indicating the lower sensitivity of this technique. Furthermore, ex vivo EPR and FLI confirmed the highest tumoral ML uptake at 4 h. Last, a Perl’s stain supported the presence of our iron-based particles in SKOV-3 xenografts. CONCLUSION: Uptake of cRGD-MLs can be visualized using both MRI and FLI, even though the latter was less sensitive due to lower depth penetration. Furthermore, our results indicate that cRGD-MLs can be used to target SKOV-3 xenograft in Swiss nude mice. Therefore, the further development of this particles into theranostics would be of interest. |
format | Online Article Text |
id | pubmed-6681073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66810732019-09-18 Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes Garcia Ribeiro, Rita Sofia Belderbos, Sarah Danhier, Pierre Gallo, Juan Manshian, Bella B Gallez, Bernard Bañobre, Manuel de Cuyper, Marcel Soenen, Stefaan J Gsell, Willy Himmelreich, Uwe Int J Nanomedicine Original Research PURPOSE: Magnetoliposomes (MLs) have shown great potential as magnetic resonance imaging contrast agents and as delivery vehicles for cancer therapy. Targeting the MLs towards the tumor cells or neovascularization could ensure delivery of drugs at the tumor site. In this study, we evaluated the potential of MLs targeting the αvβ3 integrin overexpressed on tumor neovascularization and different tumor cell types, including glioma and ovarian cancer. METHODS: MLs functionalized with a Texas Red fluorophore (anionic MLs), and with the fluorophore and the cyclic Arginine-Glycine-Aspartate (cRGD; cRGD-MLs) targeting the αvβ3 integrin, were produced in-house. Swiss nude mice were subcutaneously injected with 10(7) human ovarian cancer SKOV-3 cells. Tumors were allowed to grow for 3 weeks before injection of anionic or cRGD-MLs. Biodistribution of MLs was followed up with a 7T preclinical magnetic resonance imaging (MRI) scanner and fluorescence imaging (FLI) right after injection, 2h, 4h, 24h and 48h post injection. Ex vivo intratumoral ML uptake was confirmed using FLI, electron paramagnetic resonance spectroscopy (EPR) and histology at different time points post injection. RESULTS: In vivo, we visualized a higher uptake of cRGD-MLs in SKOV-3 xenografts compared to control, anionic MLs with both MRI and FLI. Highest ML uptake was seen after 4h using MRI, but only after 24h using FLI indicating the lower sensitivity of this technique. Furthermore, ex vivo EPR and FLI confirmed the highest tumoral ML uptake at 4 h. Last, a Perl’s stain supported the presence of our iron-based particles in SKOV-3 xenografts. CONCLUSION: Uptake of cRGD-MLs can be visualized using both MRI and FLI, even though the latter was less sensitive due to lower depth penetration. Furthermore, our results indicate that cRGD-MLs can be used to target SKOV-3 xenograft in Swiss nude mice. Therefore, the further development of this particles into theranostics would be of interest. Dove 2019-07-29 /pmc/articles/PMC6681073/ /pubmed/31534330 http://dx.doi.org/10.2147/IJN.S214041 Text en © 2019 Garcia Ribeiro et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Garcia Ribeiro, Rita Sofia Belderbos, Sarah Danhier, Pierre Gallo, Juan Manshian, Bella B Gallez, Bernard Bañobre, Manuel de Cuyper, Marcel Soenen, Stefaan J Gsell, Willy Himmelreich, Uwe Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes |
title | Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes |
title_full | Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes |
title_fullStr | Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes |
title_full_unstemmed | Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes |
title_short | Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes |
title_sort | targeting tumor cells and neovascularization using rgd-functionalized magnetoliposomes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681073/ https://www.ncbi.nlm.nih.gov/pubmed/31534330 http://dx.doi.org/10.2147/IJN.S214041 |
work_keys_str_mv | AT garciaribeiroritasofia targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT belderbossarah targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT danhierpierre targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT gallojuan targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT manshianbellab targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT gallezbernard targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT banobremanuel targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT decuypermarcel targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT soenenstefaanj targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT gsellwilly targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT himmelreichuwe targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes |